Analysts expect Anavex Life Sciences Corp. (NASDAQ:AVXL) to report $-0.10 EPS on December, 10.They anticipate $0.02 EPS change or 16.67 % from last quarter’s $-0.12 EPS. After having $-0.06 EPS previously, Anavex Life Sciences Corp.’s analysts see 66.67 % EPS growth. The stock decreased 2.01% or $0.05 during the last trading session, reaching $2.39. About 232,245 shares traded. Anavex Life Sciences Corp. (NASDAQ:AVXL) has declined 46.96% since November 14, 2017 and is downtrending. It has underperformed by 62.58% the S&P500.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer??s disease, other central nervous system diseases, pain, and various cancers. The company has market cap of $108.63 million. The company??s lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer??s disease; and in preclinical clinical trials to treat Parkinson??s disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. It currently has negative earnings. The Company’s preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer??s disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain.
More notable recent Anavex Life Sciences Corp. (NASDAQ:AVXL) news were published by: Seekingalpha.com which released: “MYnd Analytics leads healthcare gainers; Synergy Pharmaceuticals tops losers” on October 26, 2018, also Nasdaq.com with their article: “Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company …” published on November 06, 2018, Nasdaq.com published: “Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of …” on November 08, 2018. More interesting news about Anavex Life Sciences Corp. (NASDAQ:AVXL) were released by: Nasdaq.com and their article: “First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s …” published on October 30, 2018 as well as Streetinsider.com‘s news article titled: “Anavex Life Sciences (AVXL) Reports First Patient Enrolled in Phase 2 Clinical Trial of ANAVEX2-73 for Treatment of …” with publication date: October 30, 2018.